Intellia Therapeutics Investor Presentation — March 2022

Document content

Intellia is Leading the

Genome Editing Revolution

Bill, living with transthyretin amyloidosis, and his wife, Maura2

Intellia Therapeutics’ Legal Disclaimer

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”, “we” or“our”) within themeaning ofthePrivate Securities

Litigation Reform Actof1995 .These forward -looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s beliefs and

expectations regarding :thesafety, efficacy andadvancement ofourclinical programs forNTLA -2001 forthetreatment oftransthyretin amyloidosis, NTLA -2002

forthetreatment ofhereditary angioedema, andNTLA -5001 forthetreatment ofacute myeloid leukemia pursuant toitsclinical trialapplications (“CTA”) andIND

submissions, including theexpected timing ofdata releases, regulatory filings, andtheinitiation andcompletion ofclinical trials ;theadvancement ofdevelopment

candidates including NTLA -3001 forthetreatment ofalpha -1antitrypsin deficiency (AATD) -associated lung disease, NTLA -2003 forAATD -associated liver

disease, andNTLA -6001 forCD30+lymphomas ;theability togenerate data toinitiate clinical trials andthetiming ofCTA andINDsubmissions ;theexpansion of

itsCRISPR/Cas 9technology andrelated technologies, including manufacturing anddelivery technologies, toadvance additional development candidates ;the

ability tomaintain andexpand ourrelated intellectual property portfolio, andavoid oracquire rights tovalid intellectual property ofthird parties ;theability to

demonstrate ourplatform’s modularity andreplicate orapply results achieved inpreclinical studies, including those inourNTLA -2001 ,NTLA -5001 ,andNTLA -

2002 programs, inanyfuture studies, including human clinical trials ;itsexpectations ofRewrite Therapeutics, Inc.’s(“Rewrite”) DNA writing toadvance additional

novel platform capabilities ;theability tooptimize theimpact ofourcollaborations onourdevelopment programs, including, butnotlimited to,ourcollaboration

withRegeneron Pharmaceuticals, Inc.,including ourco-development programs forhemophilia Aandhemophilia B,withAvenCell Therapeutics, Inc.(“AvenCell ”)

forthedevelopment ofuniversal CAR -Tcelltherapies, with SparingVision SAS (“SparingVision ”)forthedevelopment ofophthalmic therapies, with Kyverna

Therapeutics, Inc.(“Kyverna ”)forthedevelopment ofKYV-201,andwith ONK Therapeutics Ltd.(“ONK”) forthedevelopment ofengineered NKcelltherapies ;

and thepotential timing and receipt offuture milestones and royalties, orprofits, asapplicable, based onourlicense, collaboration and, ifapplicable, co-

development agreements with Regeneron, Novartis Institutes forBiomedical Research ,Avencell ,SparingVision ,Kyverna ,andONK ;thetiming ofregulatory